Cellular Technology Limited (CTL) has been providing CRO services to government laboratories, pharmaceutical companies, and academic institutions for a decade. CTL specializes in cell mediated immune monitoring services for research, or preclinical/clinical trials. Specializing in high-throughput ELISPOT assays, we also perform ELISA, flow cytometry, multiplex cytokine bead arrays, and other assays, tailored to our clients' specific needs, in our GLP-compliant and CLIA-certified laboratory.
Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016 The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.
James E. Gregory, UPM Pharmaceuticals||October 7, 2015 Pharmaceutical and biopharmaceutical companies large and small are increasingly relying on third-party providers for support at all stages of drug development. To realize efficiencies, they are at the same time reducing the number of suppliers to a preferred few with whom they can form strategic partnerships.
Franklin Spriggs, Stephanie Mowery and Bo Kowalcyk, AIT Bioscience ||October 7, 2015 ADCs are a breakthrough cancer treatment that can deliver cytotoxins directly to cancer cells without the sweeping collateral damage of traditional chemotherapy.
Suhasini Sharma, Sciformix Corporation ||September 11, 2015 Global biologics market will expand to $250 billion annually by 2020, with biosimilars and non-original biologics commanding 4-10% of that market
Patricia Hurley, Joan Boren and Costantino Congiatu, PPD||June 2, 2015 More than $60 billion worth of patents on biological products are expiring before 2020, representing a major opportunity for the pharmaceutical industry.
Stephanie Mowery, Sherri Rinker, Franklin Spriggs and Bo Kowalcyk , AIT Bioscience||June 2, 2015 Moving forward clinical studies will have to include a comparative assessment of
pharmacokinetics and immunogenicity to the original reference biologic drug